Abstract Transcatheter aortic valve implantation (TAVI) is a novel therapy, which has transformed the management of inoperable patients presenting with symptomatic severe aortic stenosis (AS). It is also a proven and less invasive alternative therapeutic option for high-risk symptomatic patients presenting with severe AS who are otherwise eligible for surgical aortic valve replacement. Patient age is not strictly a limitation for TAVI but since this procedure is currently restricted to high-risk and inoperable patients, it follows that most patients selected for TAVI are at an advanced age. Patient frailty and co-morbidities need to be assessed and a clinical judgment made on whether the patient will gain a measureable improvement in their quality of life. Risk stratification has assumed a central role in selecting suitable patients and surgical risk algorithms have proven helpful in this regard. However, limitations exist with these risk models, which must be understood in the context of TAVI. When making final treatment decisions, it is essential that a collaborative multidisciplinary ''heart team'' be involved and this is stressed in the most recent guidelines of the European Society of Cardiology. Choosing the best procedure is contingent upon anatomical feasibility, and multimodality imaging has emerged as an integral component of the pre-interventional screening process in this regard. The transfemoral route is now considered the default approach although vascular complications remain a concern. A minimal vessel diameter of 6 mm is required for currently commercial available vascular introducer sheaths. Several alternative access routes are available to choose from when confronted with difficult iliofemoral anatomy such as severe peripheral vascular disease or diffuse circumferential vessel calcification. The degree of aortic valve leaflet and annular calcification also needs to be assessed as the latter is a risk factor for postprocedural paravalvular aortic regurgitation. The ultimate goal of patient selection is to achieve the highest procedural success rate while minimizing complications and to choose patients most likely to derive tangible benefit from this procedure.
Introduction
Transcatheter aortic valve implantation (TAVI) is a novel therapeutic modality to treat high-risk or inoperable patients presenting with symptomatic severe aortic stenosis (AS) [1, 2] . Appropriate patient selection is critical to the success of this procedure and must take into consideration several clinical and anatomical factors [3] . Clinical factors include a careful assessment of symptomatic status, aortic stenosis severity and patient risk profile. Risk stratification has assumed a key role in patient selection and the most recent guidelines from the European Society of Cardiology (ESC) have stressed the importance of a multidisciplinary ''heart team'' approach to help determine this risk [4] . Traditionally, algorithms derived from cardiac surgical patients have been used as an adjunct to help quantify risk among patients undergoing TAVI [5] . However, there are inherent limitations with this approach, mainly deriving from the fact that existing risk algorithms are being applied to procedures and patient populations for which they were not originally intended [6] . Consequently, the use of risk models alone may not provide a satisfactory risk assessment and other clinical factors must be considered [5] .
Anatomical elements include a comprehensive assessment of the peripheral vessels, aorta, aortic annulus, left ventricular outflow tract (LVOT) and left ventricle. Multimodality imaging plays a pivotal role in this regard [7] . Understanding the topographic anatomy of the aortic valve complex and its relationship to surrounding structures such as the atrioventricular conduction system, mitral valve apparatus and coronary ostia is crucial [8] . Selection of prosthesis type and size relies on precise measurements of the aortic valve annulus, whereas selection of the procedural approach depends in large part on the luminal diameter, calcific burden and tortuosity of the peripheral arteries and/or the presence of significant atheroma within the thoracic aorta.
How to choose the suitable patient

Clinical factors
According to recent ESC guidelines, TAVI is indicated to treat symptomatic severe aortic stenosis in selected high risk or inoperable patients as assessed by a ''heart team'' [4] . The latter should comprise cardiologists, cardiac surgeons and other specialists if deemed necessary. The guidelines state that selected patients should be expected to gain improvement in their quality of life and to have a life expectancy of [1 year after consideration of their comorbidities [4] . A recently proposed algorithm for clinical decision making in TAVI is shown in Fig. 1 [9] . It should be noted that some patients are even too high risk for TAVI and significant co-morbidities (e.g., severe COPD) may lead to continued impaired quality of life and impact on mortality even after TAVI [10] .
Risk assessment
Traditionally, surgical risk scores have been used to assess patient risk and there are several risk scoring systems available for those undergoing surgical aortic valve replacement (SAVR) ( Table 1 ) [11] [12] [13] [14] [15] [16] [17] [18] [19] . The most widely used risk algorithms are the European System for Cardiac Operative Risk Evaluation (EuroSCORE) and the Society of Thoracic Surgeons Predicted Risk Of Mortality (STS-PROM) scores [11, 13] . These scores, in general, provide reasonable discrimination, i.e. overall estimation of risk category, but cannot be used to estimate the precise operative mortality in an individual patient because of poor calibration, particularly in high-risk patients [5] . For example, in the high-risk Placement of Aortic Transcatheter Valves (PARTNER) A cohort, the mean STS-PROM Fig. 1 Clinical decision algorithm for patients presenting with severe symptomatic aortic stenosis. Adapted and modified from Webb et al. [9] with permission from Elsevier. AVR aortic valve replacement, TAVI transcatheter aortic valve replacement scores were 11.8 and 11.7 % and the mean logistic EuroSCOREs were 29.3 and 29.2 % in the TAVI and SAVR groups, respectively [20] . However, the observed 30-day mortality rates were lower at 3.4 and 6.5 % in the respective groups [20] . In fact, the logistic EuroSCORE has been shown to overpredict expected mortality by a factor of three or more in high-risk candidates for SAVR [6] . This poor calibration among high-risk valvular disease patients relates to the fact that the EuroSCORE model was developed and validated in a population of lower risk patients undergoing predominantly coronary artery bypass grafting (CABG) almost two decades ago [11] . The STS-PROM risk model for SAVR is more precise, which is not surprising given that it was developed and validated in a more contemporary group of patients exclusively undergoing isolated aortic valve replacement [13] . The EuroSCORE II model, which was developed and validated in a large contemporary population of patients recruited worldwide [14] , was found to be better calibrated than the logistic EuroSCORE in predicting outcomes after TAVI [21, 22] . However, almost half of recruited patients underwent CABG, thereby limiting its applicability to patients undergoing exclusively valvular procedures. The recent German Aortic Valve (AV) Score was developed from a population of patients entirely undergoing aortic valve procedures [isolated SAVR (n = 10,574) or TAVI (n = 573)] throughout Germany in 2008 [16] . This novel risk model appears promising, although further studies are required to assess the discrimination and calibration of the German AV Score among a TAVI population. A major limitation in applying cardiac surgical risk models to TAVI patients is that there are several variables that impact upon clinical outcomes among selected patients undergoing TAVI that are not captured, including liver disease, porcelain aorta, adherent coronary artery bypass grafts, previous radiation to the chest, and frailty [5] . While surgical risk scores are not perfect when applied to a TAVI patient population, they are currently the best available risk stratification tools and should be used as an adjunct to estimate patient risk. However, they should not be used in isolation and clinical judgment is required. Whether a dedicated ''TAVI risk score'' will improve discrimination and calibration remains to be seen.
Anatomical factors
Peripheral arteries
The peripheral arteries can be imaged using a variety of methods, including contrast angiography, intravascular ultrasound, multidetector computed tomography (MDCT) or magnetic resonance imaging (MRI) (Fig. 2) . Important parameters to consider are the diameter, extent of calcification and tortuosity of the peripheral arteries as well as their combination. The ratio between the outer sheath diameter and the internal diameter of the femoral artery using quantitative angiography yields the Sheath to Femoral Artery Ratio (SFAR) [23] . An SFAR ratio of [1.05 has been shown to predict Valvular Academic Research Consortium (VARC) defined major vascular complications and 30-day mortality in one study [23] . However, the SFAR ratio can be increased to 1.10 in the absence of significant calcification, but is reduced to 1.00 in the presence of circumferential calcification [23] . A recent study showed that vascular complications are more frequent in three scenarios: (1) minimal artery diameter is smaller than the external sheath diameter (2) moderate or severe vessel calcification and (3) peripheral vascular disease [24] . Contrast angiography can provide a gross assessment of lumen diameter and vessel tortuosity of the peripheral vessels and enables internal diameter measurement [25] . However, MDCT is assuming a more prominent role for imaging the peripheral vessels owing to improved definition and its 3 dimensional (3D) capabilities [26] . Furthermore, the use of CT image post-processing software such as 3-mensio Valves TM (3mensio Medical Imaging BV, Bilthoven, The Netherlands) allows for the 3D reconstruction of the iliofemoral arteries and descending aorta in a simplified manner [27] . In general, the side with the larger, less tortuous, less diseased iliofemoral artery is selected for sheath insertion. The transfemoral approach should be avoided in patients with vessel diameters too small to accommodate the introducer sheaths (Table 2 ) and in patients with severe peripheral vascular disease and diffuse circumferential severe calcification of the iliofemoral vasculature.
Ascending aorta
Accurate measurement of ascending aortic diameter is important for the self-expanding Medtronic CoreValve bioprosthesis (Medtronic, Inc. Minneapolis, Minnesota), because the outflow portion of the frame abuts this region of the vessel wall to orient the prosthesis in the direction of blood flow [28] . A dilated ascending aorta ([43 mm) is a relative contraindication for Medtronic CoreValve implantation. Adequate sinus of Valsalva dimensions is also necessary to accommodate the displaced native leaflets following CoreValve implantation. Balloon-expandable SAPIEN valves (Edwards Lifesciences, Inc., Irvine, CA, USA), once implanted, are located almost exclusively within the annular plane and, therefore, ascending aorta dimensions are less relevant. Critically important for these prostheses, however, is the height between the aortic annulus and the right and left coronary ostia (Fig. 3 ) [28] . Coronary obstruction may occur when a bulky calcified aortic valve leaflet is compressed against the coronary ostium following implantation of a balloon-expandable valve. Therefore, a minimum distance of 8-10 mm between the coronary ostia and aortic annular plane is recommended by the manufacturer when implanting a SAPIEN valve [28] . In the presence of adequate sinus of Valsalva dimensions, this annular-ostial height prerequisite is not essential for CoreValve implantation, owing to its constrained mid portion. Fig. 2 Imaging of the femoral arteries using contrast angiography (a) and threedimensional reconstruction using multidetector computed tomography (MDCT) (b). Preinterventional multimodality imaging is important to assess the minimal femoral diameters, calcific burden and degree of tortuosity of the peripheral vessels
Aortic annulus
Precise annular measurements using non-invasive imaging are crucial for procedural success and avoidance of complications. In addition, a detailed knowledge of aortic root anatomy is essential. The surgical aortic annulus is a semilunar crown-like ring delineated by the hinges of the aortic valve leaflets [8] . The aortic annulus used for the purposes of aortic prosthesis sizing concerns a virtual ring formed by the basal attachments of the aortic valve cusps located at the base of the crown (Fig. 4) . This virtual ring is distinct from the anatomic ventriculoarterial junction, which is located slightly more distally within the aortic root [8] . The ring formed at the top of the crown represents a true ring and forms the sinotubular junction, which demarcates the border between the aortic root and the ascending aorta. In the context of TAVI, noteworthy structures in close proximity to the aortic valve complex include the anterior mitral valve leaflet and left bundle branch [8] . The noncoronary and left coronary aortic leaflets are in fibrous continuity with the anterior mitral valve leaflet, which together form the aortic-mitral curtain. The left bundle branch is located close to the base of the interleaflet triangle separating the non-coronary and right coronary leaflets of the aortic valve [8] .
Accurate aortic annular measurements are critical to avoid annulus-prosthesis mismatch [29] . The latter may lead to either undersizing or oversizing of transcatheter heart valve (THV) prostheses [29] . Undersizing may result in paravalvular regurgitation and/or device embolization, whereas oversizing may cause underexpansion of the prosthesis, conduction disturbances or annular rupture. A recent study reported that aggressive annular area oversizing (C20 %) was associated with an increased risk of aortic root rupture (odds ratio 8.38) during TAVI with balloon-expandable prostheses [30] . A certain degree of oversizing is necessary, however, to anchor the sutureless prosthesis to the annular wall and provide adequate sealing against paravalvular aortic regurgitation. Caution is required though, particularly in the presence of excessive valvular calcification as well as calcification extending into the LVOT or ascending aorta [30] .
Traditionally, annular diameters were measured as the distance between the hingepoints of the right and noncoronary aortic cusps in mid systole from a parasternal long-axis view in transthoracic echocardiography (TTE) or a 120°-140°long-axis view (3-chamber view) in transesophageal echocardiography (TEE) (zoomed mode) [31] . In addition, the annulus can be measured following aortic root angiography [28] . However, these measurements provide only 2 dimensional assessments of the aortic annulus and ignore its 3D configuration. In addition, a recent study reported that the aortic annulus is oval in shape in over 90 % of cases [32] . Therefore, TTE and TEE may only provide tangential measurements, which may not reflect the true annular diameter. Using MDCT, 3D reconstruction is possible and, therefore, this imaging modality assumes a more prominent role in aortic annular assessments (Fig. 5 ) [33] [34] [35] . MDCT measurements are taken from systolic phase reconstructions ranging from 20 to 45 % of the R-R interval, during retrospective electrocardiographic gating imaging, using the phase with maximum valve opening [26] . The aortic annulus plane is obtained by a double oblique multiplanar reconstruction with 2 orthogonal planes representing the short and long axis of the virtual basal ring [26] . Patients with chronic renal insufficiency undergoing TAVI may be at higher risk of acute renal failure when exposed to contrast agents during the course of MDCT screening or left heart catheterization prior to the TAVI procedure. Therefore, a staged procedure should be recommended if MDCT screening is used. Alternatively, annulus sizing might be achieved using rotational angiography (Dyna-CT) or 3D-TEE during the same procedure. A recent study showed that patients with baseline chronic kidney disease (CKD) undergoing TAVI were at no higher risk of acute kidney injury, renal replacement therapy and mortality than patients without CKD [36] .
Considerable debate exists regarding the best parameter for annular sizing [30, 34, 37, 38] . While diameter measurements are recommended by manufacturers' guidelines, some argue that area measurements are more reproducible and have been shown to be predictive of greater than mild paravalvular regurgitation [37, 38] . Others have advocated perimeter annular measurements owing to less variability across the cardiac cycle [39] . In addition, perimeter measurements are less affected by the morphological transformation of the annulus (i.e. change from oval to circular shape) that may occur following prosthesis (particularly balloon expandable) implantation [39] .
When determining prosthesis size based on MDCT diameter measurements, mean annular diameters (D mean ) derived from the minimal diameter (D min ; measured in the sagittal view) and maximal diameter (D max ; measured in the coronal view) (D mean = (D min ? D max )/2) or virtual aortic annular diameters should be used [33] . The latter can be calculated using either annular perimeter (D perimeter = perimeter/p) or annular area (D area ¼ 2 Â ffiffiffiffiffiffi area p p ) [33] . The MDCT sagittal view corresponds to the parasternal longaxis view on TTE and the 20°-140°long-axis view on TEE [29] . In general, annular diameters measured using TTE are smaller than those sized using TEE and both tend to be smaller than those measured on the MDCT coronal view [29] .
Patients with annuli too large for currently available THV prostheses ([29 mm) are not suitable for TAVI. In addition, patients with large annuli and/or low-grade calcification might be at particular risk for valve displacement and this should be noted during multimodality imaging. Fig. 3 Calculating the distance between the aortic annular plane and left (a) and right (b) coronary ostia using multidetector computed tomography (MDCT). A recent study using MDCT revealed that the mean distance between the aortic annulus and left coronary artery is 14.4 ± 3.6 mm and the mean distance between the aortic annulus and right coronary artery is 16.7 ± 3.6 mm [30] .
Aortic valve leaflets
Aortic valve leaflet morphology and anatomy should be evaluated. Bicuspid aortic valve anatomy is currently considered a relative contraindication for TAVI [4] . The elliptical annulus, asymmetric aortic cusps and a raphe of fusion between two cusps have raised concerns regarding prosthesis deployment and the increased risk of paravalvular regurgitation [40] . However, individual case reports and small case series have demonstrated feasibility and short-term clinical outcomes appear promising [40] but larger patient series and longer term follow-up are needed. In addition, severe calcification of the aortic valve leaflets, particular if asymmetrical, is a known cause of paravalvular aortic regurgitation and, therefore, should be evaluated during the screening process [41] .
Cardiac factors
The degree of LVOT calcification should be evaluated preferably using MDCT. A recent study reported that moderate-severe calcification of the LVOT was associated with an increased risk of aortic root rupture during TAVI with balloon-expandable prostheses [30] . In cases of a pronounced sigmoid septum, the transapical approach may be preferred to allow adequate positioning and anchorage of the prosthesis [42] . Fig. 4 The aortic annulus used for the purposes of aortic prosthesis sizing concerns a virtual ring formed by the basal attachments of the aortic valve cusps located at the base of the crown. The ring formed at the top of the crown represents a true ring and forms the sinotubular junction. Figure  adapted 
Coronary artery disease
Significant coronary artery disease is present in 40-75 % of patients undergoing TAVI [43] . Patients with coronary artery disease tend to have higher surgical risk scores and associated comorbidities than those without. The general consensus is that revascularization should be considered for severe coronary stenosis in proximal epicardial coronary vessels that subtend a large area of myocardium [43] . However, patients with severe aortic stenosis and triple vessel disease with a SYNTAX score C33 should be considered for SAVR where feasible [43] . There is also debate regarding the timing of revascularization. Although both concomitant and staged strategies have been reported successfully [44] , the latter approach appears to be more commonly used [43] .
Low-flow, low-gradient severe aortic stenosis
A very low LVEF (\30 %) among patients with severe AS has a negative prognostic impact in patients treated conservatively [45] . However, patients presenting with a low LVEF and high gradient generally have better LVEF recovery following SAVR as compared with patients with a low LVEF in combination with a low mean gradient [46] . The latter condition is referred to as low-flow (i.e. LVEF B40 %), low-gradient (mean gradient B40 mmHg but aortic valve area\1 cm 2 ) (LFLG) severe AS and is present in 5-10 % of patients presenting with severe AS [47] . This condition is challenging to manage because conservatively managed patients have a dismal prognosis, yet those undergoing SAVR have a high perioperative mortality, particularly in the absence of contractile reserve [48] . A recent sub-analysis of the PARTNER trial revealed that 2-year mortality was significantly reduced (HR 0.43, p = 0.04) with TAVI as compared with medical management among patients (n = 42) with LFLG severe AS from the inoperable B cohort [49] . Recently, it was demonstrated that patients with LFLG severe AS had overall 30-day and 1-year mortality rates similar to high-gradient patients following TAVI, albeit with an higher incidence of 1-year cardiac mortality among LFLG patients [50] . It was also found that patients with a low LVEF (B40 %) and highgradient (mean gradient [40 mmHg) had significantly improved LVEF recovery following TAVI as compared to patients with LFLG severe AS [50] . In 2007, a novel entity, paradoxical low-flow (LVEF C50 %, but stroke volume index (SVI) B35 mL/m 2 ), low-gradient (B40 mmHg) severe AS (AVA \1 cm 2 ) (PLF-LG) was described and symptomatic patients managed conservatively had a higher mortality compared to patients undergoing SAVR [51] . Herrmann et al. in a post hoc analysis of the PARTNER trial showed that among the cohort of patients with PLF-LG, those undergoing TAVI had significantly improved survival when compared with patients undergoing medical management [49, 52] . A recent study reported that PLF-LG patients undergoing TAVI have a high arterial afterload despite a low mean gradient and that these patients derive functional benefit from TAVI with clinical outcomes similar to high-gradient patients [50] .
Contraindications to TAVI
Clinical contraindications include a life expectancy \1 year or unlikely improvement in quality of life by TAVI because of comorbidities [4] . Severe concomitant primary disease of other valves which contribute predominantly to the patients' symptoms and can only be treated by surgery is another contraindication [4] . Anatomical contraindications include inadequate annulus size (\18 mm or [29 mm), presence of left ventricular thrombus, active endocarditis, high risk of coronary obstruction (asymmetric valve calcification, short annularostial distance, small aortic sinus dimensions), large plaques with mobile thrombi in the ascending aorta or arch or inadequate vascular access (for transfemoral/subclavian approach) due to vessel size, calcification or tortuosity [4] . In addition, the ESC guidelines have stressed the absence of a ''heart team'' and on-site cardiac surgery as contraindications to TAVI [4] . Relative contraindications include bicuspid or non-calcified valves, and untreated coronary artery disease requiring revascularization. For the transapical approach, severe pulmonary disease and an inaccessible LV apex remain important caveats [4] .
How to choose the best procedure
Transcatheter heart valve bioprosthesis Nine THV bioprostheses have received Conformité Européenne (CE) mark approval at the time of writing (January 2014) ( Table 3 The Edwards SAPIEN XT is a balloon-expandable prosthesis made from a cobalt-chromium frame, trileaflet bovine pericardial leaflets, and polyethylene terephthalate (PET) fabric skirt [53] . The leaflets undergo a proprietary anti-calcification treatment (ThermaFix TM ) process [53] . The Edwards SAPIEN XT is available in 4 sizes (20, 23, 26 , and 29 mm) and can be implanted in native annuli with diameters of 16-27 mm. The current third-generation Medtronic CoreValve bioprosthesis is a self-expandable valve, comprising a nitinol frame, trileaflet porcine pericardial leaflets, and porcine pericardium fabric skirt. The leaflets also undergo an anti-calcification treatment using AOA (alpha-amino-oleic acid). The CoreValve is currently available in 4 sizes (23, 26, 29, 31 mm) and can be implanted in native annuli with diameters ranging from 20 to 29 mm. The valve has received CE mark approval for implantation via the transfemoral, transaxillary/transsubclavian and direct aortic routes.
Instances when a self-expandable devices may be preferable over a balloon-expandable prosthesis include patients with large annuli ([27 mm), heavy calcification of the aortic annulus/LVOT with an attendant risk of rupture, very low take off of the coronary arteries (\8 mm), small left ventricular cavity, severely depressed LVEF (since at least one episode of rapid pacing can be omitted), extremely oval-shaped annulus or valve-in-valve procedures with small surgical prostheses [54] . Conversely, a balloonexpandable device may be preferable among patients with a dilated ascending aorta ([43 mm), a high risk of atrioventricular conduction disturbances (e.g., right bundle branch block on baseline electrocardiogram) or a horizontal ascending aorta (consider transapical approach) [54] . In patients eligible for either prosthesis, choice generally comes down to operator and/or institutional preference.
Access
The transfemoral route is generally considered the default approach when feasible as it is least invasive. The fact that transfemoral TAVI can be performed as a completely percutaneous procedure in a consciously sedated patient under local anesthesia has resulted in shorter procedural times, shorter length of hospital stay and earlier mobilization [55, 56] . Concerns with this approach relate mainly to vascular complications, which have been shown to have an adverse impact on clinical outcomes [57] . In the FRANCE 2 registry (n = 3,195), three quarters of patients underwent TAVI via the transfemoral route [58] . Advantages with the transapical approach include a low risk of peripheral vascular injury, a direct pathway to the aortic valve, and easier antegrade crossing of the aortic valve [59] . Problems relate to direct myocardial injury, bleeding, injury to the mitral valve apparatus, hemodynamic instability, need for orotracheal intubation, post-operative respiratory compromise and thoracotomy pain [59] . Among patients with unfavorable iliofemoral anatomy, the Medtonic CoreValve can be inserted via the transaxillary/ transsubclavian route [60] . In the absence of calcification, the minimum artery diameter should be at least 6 mm for an 18F sheath but in patients with a patent left internal mammary artery graft, the diameter should be C7.5 mm in order not to obstruct flow to the graft [61] . Normally, a surgical cut-down is performed, but a fully percutaneous procedure has been described [62, 63] . The direct aortic approach can be performed via a small right upper ''J'' hemisternotomy or a small right anterior thoracotomy and has become increasingly popular for implantation of both the Medtronic CoreValve and the Edwards SAPIEN devices [64] . Advantages with the direct aortic approach include direct access to a large-calibre vessel, thereby avoiding smaller arteries like the iliofemoral or subclavian artery, a more direct pathway to the aortic valve and an operating technique familiar to surgeons [54] .
Different sheath sizes are available depending on the size and make of the transcatheter heart valve prosthesis and access route chosen. For the transfemoral route, the Edwards e-Sheath, used with the NovaFlex ? delivery system (Edwards Lifesciences, Inc., Irvine, CA, USA), comes in 16F, 18F and 20F for the 20 and 23 mm (16F), 26 mm (18F) and 29 mm (20F) Edwards SAPIEN XT THV, respectively. The e-Sheath has a Dynamic Expansion Mechanism enabling temporary expansion of the sheath during passage of the transcatheter heart valve before resuming its unexpanded shape. Minimal femoral artery diameters are 6 mm for the 20 mm and 23 mm SAPIEN XT, 6.5 mm for the 26 mm SAPIEN XT and 7.0 mm for the 29 mm SAPIEN XT prostheses, respectively ( Table 2 ). The ASCENDRA-II TM system (Edwards Lifesciences, Inc., Irvine, CA, USA), used for the transapical approach, requires the use of either a 24F (23 and 26 mm SAPIEN XT) or a 26F (29 mm SAPIEN XT) introducer sheath.
In the current iteration of the Medtronic CoreValve system, the 18F introducer sheath is not supplied. Available sheaths for use with this system include the Check-Flo TM sheath (Cook Medical Inc., Bloomington, IN, USA), Ultimum TM sheath (St. Jude Medical, Inc., St. Paul, MN, USA) Gore DrySeal TM Sheath (Gore Medical Inc., AZ, USA) or the SoloPath TM sheath (Onset Medical Corp. CA, USA). The latter is a 14F expandable sheath and can be dilated to over 18F with a balloon once introduced into the artery, theoretically reducing the risk of arterial injury during sheath insertion [65] . Sheath dimensions and minimal vascular dimensions are shown in Table 4 .
Prevention of complications
Meticulous pre-procedural planning can minimize the occurrence of complications. Vascular complications remain an important concern with TAVI [57] . Using the large diameter 22F and 24F RetroFlex delivery system, the incidence of major vascular complications was 10.6, 11.0 and 16.2 % in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry and PARTNER IA & B trials, respectively [20, 66, 67] . Using the lower profile NovaFlex delivery systems, the SOURCE XT registry recently reported a reduced major vascular complication rate of 7.5 % [68] . In addition, the PARTNER 2B trial revealed that ''inoperable'' patients undergoing TAVI with the newer generation SAPIEN XT and NovaFlex delivery system (18F and 19F) had a significantly lower rate of major vascular complications as compared with those undergoing TAVI with the earlier generation SAPIEN and RetroFlex 3 delivery system (22F and 24F) (9.6 vs 15.5 %, p = 0.04) [69] . This was mainly driven by reductions in vascular perforations and dissections in the SAPIEN XT cohort [69] . In addition to the use of smaller sheaths, angiographic and computed tomographic screening and patient selection have also been shown to reduce vascular complications [24] . Therefore, rigorous screening of the peripheral vessels is essential. Stroke has emerged as an important consideration. Major stroke was reported at a rate of 3.8 and 5.0 % in the PARTNER A and B cohorts, respectively [20, 67] . Predictors of cerebrovascular events included prior stroke, smaller indexed aortic valve area, higher NYHA functional class and transapical access [70] . An increased risk of neurological events was observed in both SAVR and TAVI groups during the course of the first week, but there was no subsequent increased risk over SAVR up until 2 years [70] . Strategies suggested to reduce the acute stroke rate include omitting balloon aortic valvuloplasty, minimizing the passage of guide wires and catheters across the aortic arch and the use of embolic protection devices. Atrioventricular conduction disturbances requiring permanent pacemaker (PPM) insertion are more frequent after TAVI than after SAVR with the use of self-expanding Medtronic CoreValve prosthesis but not with the balloon-expandable SAPIEN valve [20] . Mechanical trauma to the left bundle branch or His bundle located near the subannular membranous septum may be responsible [71] . Predictors of PPM insertion include preexisting RBBB, balloon pre-dilatation, and prolonged QRS duration [72] . A recent study reported that survival up to 1-year follow-up was not worse among patients requiring a PPM after TAVI, but the long-term effects of right ventricular pacing remain unknown [73] . Paravalvular regurgitation is the result of prosthesis undersizing, malpositioning or malapposition secondary to excessive or asymmetric calcification [41, 74] . Moderate or severe paravalvular regurgitation at 30 days was reported in 12.2 and 11.8 % of patients after TAVI in the PARTNER A & B cohorts, respectively, as compared with just 0.9 % in the PARTNER A SAVR cohort [20, 67] . Several studies have shown that moderate or severe paravalvular regurgitation is associated with impaired prognosis after TAVI [75, 76] Accurate annular measurements are important to avoid undersizing, and multimodality imaging can help assess the extent and location of calcification.
Future perspectives
Further refinements in patient selection and technological improvements in transcatheter delivery systems and bioprostheses are anticipated in the future. Several new transcatheter heart valve prostheses are in the pipeline (Table 5 ). Improved methods of patient risk stratification are required and ideally a dedicated ''TAVI risk score'' should be developed and validated in a large population of TAVI patients. Further downsizing of the introducer sheath may reduce the incidence of vascular complications. For example, the newer generation Edwards SAP-IEN 3 TM (Edwards Lifesciences, Inc., Irvine, CA, USA) can be introduced via a 14 F introducer sheath using the Commander TM delivery system (Edwards Lifesciences, Inc., Irvine, CA, USA) [77] . The Medtronic CoreValve Evolut R TM (Medtronic, Minneapolis, MN, USA) will be delivered via the EnVeo R delivery system, which also has a 14F inner diameter. In addition, percutaneous closure systems with reliable performance are needed. The incidence of paravalvular aortic regurgitation may be reduced by the development of completely repositionable and retrievable devices to immediately correct malpositioning. This is now possible with several newer generation THV bioprostheses, including the St. Jude Medical Portico TM (St. Jude Medical, St. Paul, Minnesota), and Sadra Medical Lotus TM (Boston Scientific, Natick, Massachusetts) bioprostheses. In addition, newer generation THV bioprostheses such as the Edwards SAPIEN 3 TM (Edwards Lifesciences, Inc., Irvine, CA, USA) have unique sealing mechanisms to further reduce paravalvular aortic regurgitation. Other refinements needed are mechanisms to reduce stroke risk and heart block. TAVI has already been performed in lower risk patients and clinical outcomes are in fact better [78] . The extension of TAVI to intermediate-risk patients is currently the subject of the ongoing SURTAVI and PARTNER 2A randomized clinical trials. Further data on long-term valve durability are also required.
Conclusions
The success of TAVI over the past decade can be attributed in large part to the rigorous preinterventional screening of clinical and anatomical patient characteristics and to the multidisciplinary collaborative approach in selecting the most appropriate patients for this procedure. Multimodality imaging has also played a role. Further refinements in risk 
